Memo Therapeutics AG’s Post

Memo Therapeutics AG reposted this

View organization page for Memo Therapeutics AG, graphic

4,467 followers

View profile for Lars Spenger, graphic

CFO at Memo Therapeutics AG

🎉 🎉 🎉 A huge thank you to everyone involved for getting our Series C Extension over the finish line! To name a few: 💉 New investors: Thomas Harth (Ysios Capital), Hadrien Bouchez (Kurma Partners) 💉 Existing investors: Veronica Gambillara Fonck (Pureos Bioventures), Robert Schier (Swisscanto), Philippe Dro (Adjuvant Capital), Christian Schneider (Vesalius Biocapital III) 💉 Legal: Oliver Gnehm (BGPartner | Attorneys-at-law), Matthias Staehelin (Vischer) The incremental funds will be used to expand Phase II of our best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation. Initial data from the Phase II trial is expected in the first half of 2025. #Transplantation #Nephrology https://lnkd.in/dRsEr7g3

Memo Therapeutics increases Series C financing to CHF 45 million

Memo Therapeutics increases Series C financing to CHF 45 million

memo-therapeutics.com

To view or add a comment, sign in

Explore topics